NCT06902857 Study on the Predictive Value of High-sensitivity Cardiac Troponin I, N-terminal Pro-B-natriuretic Peptide, and Soluble Suppression of Tumorigenesis-2 for Mortality and the Development of Cardiovascular Events in Patients With Type 2 Diabetes (Diabetes-CV)
| NCT ID | NCT06902857 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Istituto Nazionale di Ricovero e Cura per Anziani |
| Condition | Type 2 Diabetes |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,002 participants |
| Start Date | 2024-04-18 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,002 participants in total. It began in 2024-04-18 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Diabetes-CV study is an observational study designed to assess the prognostic value of serum cardiac damage markers high-sensitivity cardiac troponin I (hs-cTnI), N-terminal pro-B-natriuretic peptide (NT-proBNP), and soluble suppression of tumorigenesis-2 (sST2) in predicting mortality, major adverse cardiovascular events, and diabetic complications in patients with type 2 diabetes.
Eligibility Criteria
Inclusion Criteria: * type 2 diabetes * patients attending the outpatient services Exclusion Criteria: * type 1 diabetes * patients with active cancer or cancer in remission for less than 5 years * any medical or other reason that leads the investigator to consider the subject ineligible for the study.
Contact & Investigator
Elena Tortato, MD
PRINCIPAL INVESTIGATOR
IRCCS INRCA, Ancona, Italy
Frequently Asked Questions
Who can join the NCT06902857 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Type 2 Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06902857 currently recruiting?
Yes, NCT06902857 is actively recruiting participants. Contact the research team at a.bonfigli@inrca.it for enrollment information.
Where is the NCT06902857 trial being conducted?
This trial is being conducted at Ancona, Italy.
Who is sponsoring the NCT06902857 clinical trial?
NCT06902857 is sponsored by Istituto Nazionale di Ricovero e Cura per Anziani. The principal investigator is Elena Tortato, MD at IRCCS INRCA, Ancona, Italy. The trial plans to enroll 1,002 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.